Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now ...

Topline pivotal Phase 3 firmonertinib data. ArriVent anticipates having topline firmonertinib monotherapy data from the event-driven global pivotal FURVENT Phase 3 (NCT05607550) study in 2025 and ...

Researchers developed a biomimetic nanovesicle that crosses the blood-brain barrier, degrades DNA repair proteins, and ...

That's why all the top weight loss supplements are also metabolism boosters. Metabolism booster supplements are designed to ...